分子肿瘤学委员会用于癌症患者临床决策的真实世界经验。

Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients.

作者信息

Herrero Colomina Julio, Johnston Eleanor, Duffus Kate, Zaïr Zoulikha M, Thistlethwaite Fiona, Krebs Matthew, Carter Louise, Graham Donna, Cook Natalie

机构信息

The Christie NHS Foundation Trust, Manchester, UK.

Division of Cancer Sciences, University of Manchester, Manchester, UK.

出版信息

NPJ Precis Oncol. 2025 Mar 25;9(1):87. doi: 10.1038/s41698-025-00863-3.

DOI:10.1038/s41698-025-00863-3

PMID:40133697

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11937402/

Abstract

Molecular Tumour Boards (MTBs) play a crucial role in interpreting genomic results and providing treatment recommendations. We investigated the real-world impact of MTBs on clinical decision-making by surveying health care professionals (HCPs) across the UK; 44 participants from 11 MTBs took part in the study. 97.7% of respondents felt that MTBs increased awareness of available clinical trials matched to genomic alterations, 84% reported more confidence in interpreting genomic data, and 95.4% valued MTBs as educational. Hurdles to the discussion at MTBs included frequency and capacity of MTBs (ctDNA), sample collection and laboratory turnaround time (Tissue samples). One-third of respondents encountered challenges attending MTBs regularly due to workload. The survey highlighted areas for optimisation, such as meeting efficiency, rapid molecular analysis turnaround time, reliable trial matching tools, and ensuring MTBs are included in HCP's job plans.

摘要

分子肿瘤委员会（MTBs）在解读基因组结果和提供治疗建议方面发挥着关键作用。我们通过对英国各地的医疗保健专业人员（HCPs）进行调查，研究了MTBs对临床决策的实际影响；来自11个MTBs的44名参与者参与了该研究。97.7%的受访者认为MTBs提高了对与基因组改变相匹配的可用临床试验的认识，84%的受访者表示在解读基因组数据方面更有信心，95.4%的受访者认为MTBs具有教育价值。MTBs讨论的障碍包括MTBs的频率和能力（循环肿瘤DNA）、样本采集和实验室周转时间（组织样本）。三分之一的受访者因工作量大而在定期参加MTBs方面遇到挑战。该调查突出了需要优化的领域，如会议效率、快速分子分析周转时间、可靠的试验匹配工具，以及确保MTBs被纳入HCP的工作计划。